European Journal of Cancer
Volume 38, Issue 10 , Pages 1348-1350 , July 2002

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme

Received 23 January 2002 ,Accepted 25 January 2002.

References 

  1. Sant M, van der Sanden G, Capocaccia R. Survival rates for primary malignant brain tumours in Europe. Eur. J. Cancer. 1998;34:2241–2247
  2. Friedman HS, Petros WP, Friedman AH, et al.  Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 1999;17:1516–1525
  3. Verschraegen CF, Natelson EA, Giovanella BC, et al.  A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs. 1998;9:36–44
  4. Verschraegen CF, Gupta E, Loyer E, et al.  A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs. 1999;10:375–383
  5. Stehlin JS, Giovanella BC, Natelson EA, et al.  A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int. J. Oncol. 1999;14:821–831
  6. MacDonald DR, Cascino TL, Schold SC, et al.  Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncology. 1990;8:1277–1280
  7. Hinz HR, Harris NJ, Natelson EA, Giovanella BC. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res. 1994;54:3096–3100
  8. Pantazis P, Harris N, Mendoza J, Giovanella B. Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur. J. Haematol. 1994;53:246–248

PII: S0959-8049(02)00070-9

European Journal of Cancer
Volume 38, Issue 10 , Pages 1348-1350 , July 2002

Article Tools

* Image Usage & Resolution